Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications
COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 29, 2026
NSABP FC-11: A phase II study of neratinib plus trastuzumab or neratinib plus cetuximab in patients with "quadruple wild-type" (KRAS/NRAS/BRAF/PIK3CA) metastatic colorectal cancer based on HER2 status: amplified, non-amplified (wild-type), or mutated.
Journal: Cancer chemotherapy and pharmacology
Published: May 14, 2025
Correction: NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.
Journal: Breast cancer research : BCR
Published: May 24, 2024
NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.
Journal: Breast cancer research : BCR
Published: October 05, 2023
Prospective Correlation of Magnetic Resonance Tumor Regression Grade With Pathologic Outcomes in Total Neoadjuvant Therapy for Rectal Adenocarcinoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 21, 2023
p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2+ breast cancer that limits trastuzumab deruxtecan efficacy.
Journal: Nature cancer
Published: April 17, 2023
Implementation of behaviour change training in practice amongst pharmacy professionals in primary care settings: Analysis using the COM-B model.
Journal: Research in social & administrative pharmacy : RSAP
Published: February 01, 2023
Mental Health Among Firefighters: Understanding the Mental Health Risks, Treatment Barriers, and Coping Strategies.
Journal: Journal of occupational and environmental medicine
Published: September 07, 2022
NSABP FC-6: Surgical conversion rate in colorectal cancer patients with unresectable, KRAS wild-type liver metastases receiving mFOLFOX7 plus cetuximab.
Journal: Journal of surgical oncology
Published: August 05, 2022
Correction to: Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology).
Journal: Breast cancer research and treatment
Published: May 04, 2022
Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology).
Journal: Breast cancer research and treatment
Published: August 23, 2021
Last Updated: 09/26/2026